These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 19123088)
1. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD]. Tatlicioğlu T Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088 [TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in airways disease. Fan Chung K Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289 [TBL] [Abstract][Full Text] [Related]
3. Roflumilast for the treatment of chronic obstructive pulmonary disease. Antoniu SA Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716 [TBL] [Abstract][Full Text] [Related]
4. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Martina SD; Ismail MS; Vesta KS Ann Pharmacother; 2006 Oct; 40(10):1822-8. PubMed ID: 16985092 [TBL] [Abstract][Full Text] [Related]
5. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Karish SB; Gagnon JM Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669 [TBL] [Abstract][Full Text] [Related]
6. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Sanz MJ; Cortijo J; Morcillo EJ Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015 [TBL] [Abstract][Full Text] [Related]
7. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease]. Kreutzkamp B Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460 [TBL] [Abstract][Full Text] [Related]
8. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865 [TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth BJ Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300 [TBL] [Abstract][Full Text] [Related]
10. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases]. Xia XD; Dai YR; Xu ZJ Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829 [No Abstract] [Full Text] [Related]
11. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. Gross NJ; Giembycz MA; Rennard SI COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815 [TBL] [Abstract][Full Text] [Related]
12. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Rennard SI; Schachter N; Strek M; Rickard K; Amit O Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413 [TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629 [TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Dastidar SG; Rajagopal D; Ray A Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865 [TBL] [Abstract][Full Text] [Related]
19. PDE4 inhibitors in COPD--a more selective approach to treatment. Vignola AM Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033 [TBL] [Abstract][Full Text] [Related]
20. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Giembycz MA Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]